ArticleAdvances in radiation oncology
Computational Analysis of Tumor Treating Fields for Non-Small Cell Lung Cancer in Full Thoracic Models.
Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Who cites it
7 citing papers in PubMed.
- Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomaterials research · 2026Review
- Gross-tumor-volume segment-anything model for medical 2D images integrating gross tumor volume-minimal feature integration technology for lung cancer segmentation.Quantitative imaging in medicine and surgery · 2026Article
- Advancement in tumor treating fields of mechanism, clinical applications, and future directions.Discover oncology · 2025Review
- Tumor treating fields enhance anti-PD therapy by improving CCL2/8 and CXCL9/CXCL10 expression through inducing immunogenic cell death in NSCLC models.BMC cancer · 2025Article
- Hydrogel and scalp/skin conductivities impact dose from tumor treating fields.Frontiers in bioengineering and biotechnology · 2025Article
- Tumor treating fields suppress tumor cell growth and neurologic decline in models of spinal metastases.JCI insight · 2024Article
- Body Fluids Modulate Propagation of Tumor Treating Fields.Advances in radiation oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Tumor Treating Fields (TTFields) are alternating electric fields at 150 to 200 kHz that exert their anticancer effect by destroying tumor cells when they undergo mitosis. TTFields are currently being tested in patients with non-small cell lung cancer with advanced disease (NCT02973789) and those with brain metastasis (NCT02831959). However, the distribution of these fields within the thoracic compartment remains poorly understood. Methods and Materials: Using positron emission tomography-computed tomography image data sets obtained from a series of 4 patients with poorly differentiated adenocarcinoma, the positron emission tomography-positive gross tumor volume (GTV), clinical target volume (CTV), and structures from the chest surface to the intrathoracic compartment were manually segmented, followed by 3-dimensional physics simulation and computational modeling using finite element analysis. Electric field-volume histograms, specific absorption rate-volume histograms, and current density-volume histograms were generated to produce plan quality metrics (95%, 50%, and 5% volumes) for quantitative comparisons between models. Results: Unlike other organs in the body, the lungs have a large volume of air, which has a very low electric conductivity value. Our comprehensive and individualized models demonstrated heterogeneity in electric field penetration to the GTVs with differences upwards of 200% and yielded a diverse range of TTFields distributions. Target contact with the conductive pleura intensified TTFields at the GTV and CTV. Furthermore, in a sensitivity analysis, varying electric conductivity and mass density of the CTV altered TTFields coverage to both the CTV and GTV. Conclusions: Personalized modeling is important to accurately estimate target coverage at the tumor volumes and surrounding normal tissue structures in the thorax.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.